The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114. Investigators advised clinicians of the potential for dystrophies that mimic age-related ...

Aviceda Therapeutics recently appointed Jeffrey Nau, PhD, MMS, as chief executive officer. Nau comes to Aviceda with more than 20 years of experience leading and expanding biotechnology and ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education.

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

A team of Chinese researchers reported that fasting C-peptide (FCP) has a complicated relationship with the development of diabetic retinopathy (DR). Below a specific threshold, FCP exerts a ...

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

Novelty Nobility, a Korean antibody drug discovery company, recently announced it has been selected to join JLABS Korea. 1 JLABS, part of Johnson & Johnson’s global incubator network, supports ...